# Evaluation of the Safety and Efficacy of a Novel SeaLA™ Left Atrial Appendage Occluder

Study · id `cardio:ct-nct05911685` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05911685](<https://clinicaltrials.gov/study/NCT05911685>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05911685

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 163 participants.

## Technical summary

Registry record NCT05911685. Allocation not applicable; no masking; primary purpose treatment. Start 2019-03-26 (actual); primary completion 2021-01-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 163 participants (enrolled count; ClinicalTrials.gov record NCT05911685, source copy `cardio:ctgov-nct05911685-2023-06-27`, retrieved 2026-10-26)
- Started: 2019-03-26 (actual) (ClinicalTrials.gov record NCT05911685, source copy `cardio:ctgov-nct05911685-2023-06-27`, retrieved 2026-10-26)
- Primary completion: 2021-01-21 (actual) (ClinicalTrials.gov record NCT05911685, source copy `cardio:ctgov-nct05911685-2023-06-27`, retrieved 2026-10-26)
- Completion: 2025-01-21 (anticipated) (ClinicalTrials.gov record NCT05911685, source copy `cardio:ctgov-nct05911685-2023-06-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05911685, source copy `cardio:ctgov-nct05911685-2023-06-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05911685-2023-06-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of the Safety and Efficacy of a Novel SeaLA™ Left Atrial Appendage Occluder
- Condition: Atrial Fibrillation
- Intervention (Device): SeaLA™ left atrial appendage occluder
- Lead sponsor: Hangzhou Dinova EP Technology Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Hangzhou Dinova EP Technology Co., Ltd (`cardio:org-hangzhou-dinova-ep-technology-co-ltd`)

## Provenance

Content hash: 19c506f9b6512f12f065d91fd6a53fa42eca6fff7ef37282aa3d0d9003310560
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
